As CaMKI, CaMKII and CaMKIV control cancer cell proliferation, migration and survival in a variety of cancer types in vitro (Table 2), inhibiting the activity of these kinases using KN-62 and KN-93 may be a valid anti-cancer therapeutic strategy for a range of cancer types. Here, CAMK2G is linked to cancer.